Results 41 to 50 of about 775,328 (297)

Toward Minimal Residual Disease-Directed Therapy in Melanoma.

Cell, 2018
Many patients with advanced cancers achieve dramatic responses to a panoply of therapeutics yet retain minimal residual disease (MRD), which ultimately results in relapse. To gain insights into the biology of MRD, we applied single-cell RNA sequencing to
F. Rambow, A. Rogiers, O. Marin‐Bejar, S. Aibar, Julia Femel, M. Dewaele, Panagiotis Karras, D. Brown, Y. Chang, M. Debiec-Rychter, C. Adriaens, E. Radaelli, P. Wolter, Oliver Bechter, R. Dummer, M. Levesque, A. Piris, Dennie T. Frederick, G. Boland, K. Flaherty, J. Oord, T. Voet, S. Aerts, A. Lund, J. Marine   +24 more
semanticscholar   +1 more source

Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives

Frontiers in Oncology, 2021
Circulating tumor DNA (ctDNA) is cell-free DNA (cfDNA) fragment in the bloodstream that originates from malignant tumors or circulating tumor cells. Recently, ctDNA has emerged as a promising non-invasive biomarker in clinical oncology. Analysis of ctDNA
Yan Peng, W. Mei, Kaidong Ma, Changchun Zeng   +3 more
semanticscholar   +1 more source

Molecular monitoring of minimal residual disease in two patients with MLL-rearranged acute myeloid leukemia and haploidentical transplantation after relapse [PDF]

, 2012
This report describes the clinical courses of two acute myeloid leukemia patients. Both had MLL translocations, the first a t(10;11)(p11.2;q23) with MLL-AF10 and the second a t(11;19)(q23;p13.1) with MLL-ELL fusion.
Beyer, Jörg, Blau, Igor Wolfgang, Burmeister, Thomas, Friedrichs, Birte, Lachmann, Nils, Lohm, Gunnar, Marschalek, Rolf, Meyer, Claus, Molkentin, Mara, Schwartz, Stefan, Tietze-Bürger, Carola, Uharek, Lutz   +11 more
core   +1 more source

The Minimal Residual Disease Using Liquid Biopsies in Hematological Malignancies

Cancers, 2022
Simple Summary Monitoring the response to treatment in hematologic malignancies is essential in defining the best way to optimize patient management. In general, achieving a deeper response has been shown to lead to a better prognosis, and the techniques
R. Colmenares, N. Alvarez, S. Barrio, J. Martínez-López, R. Ayala   +4 more
semanticscholar   +1 more source

Effector Functions of Natural Killer Cell Subsets in the Control of Hematological Malignancies. [PDF]

, 2015
Treatment of hematological malignant disorders has been improved over the last years, but high relapse rate mainly attributable to the presence of minimal residual disease still persists.
Biassoni, Biron, Björklund, Brodin, Bryceson, Burns, Campbell, Cooley, Cooper, Cooper, Curti, Davies, Di Santo, Di Santo, Farag, Fehniger, Fogler, Foley, Freud, Gasser, Gilfillan, Grimm, Guethlein, Herberman, Huntington, Joncker, Kiessling, Killig, King, Kröger, Lajoie, Lanier, Leong, Ljunggren, Lowe, Lundqvist, Mancusi, McQueen, Miller, Moretta, Moretta, Moretta, Nguyen, Oevermann, Ouyang, Perussia, Phillips, Romagnani, Romee, Rosenberg, Rosenberg, Rosenberg, Ruggeri, Santoni, Stabile, Stabile, Stern, Stringaris, Thielens, Torelli, Trinchieri, Trinchieri, Vago, Valés-Gómez, Venstrom, Vivier, Whitelaw, Zorn   +67 more
core   +1 more source

Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR

Journal of Clinical Oncology, 2021
PURPOSE In relapsed and/or refractory multiple myeloma, daratumumab reduced the risk of progression or death by > 60% in POLLUX (daratumumab/lenalidomide/dexamethasone [D-Rd]) and CASTOR (daratumumab/bortezomib/dexamethasone [D-Vd]).
H. Avet-Loiseau, J. San-Miguel, T. Casneuf, S. Iida, S. Lonial, S. Usmani, A. Spencer, P. Moreau, T. Plesner, K. Weisel, J. Ukropec, Christopher Chiu, Sonali Trivedi, H. Amin, M. Krevvata, P. Ramaswami, X. Qin, M. Qi, Steven Sun, M. Qi, R. Kobos, N. Bahlis   +21 more
semanticscholar   +1 more source

Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia

Haematologica, 2010
Background The presence of minimal residual disease detected by polymerase chain reaction techniques prior to allogeneic hematopoietic stem cell transplantation has proven to be an independent prognostic factor for poor outcome in children with acute ...
Izaskun Elorza, Carlos Palacio, Jose Luis Dapena, Laura Gallur, José Sánchez de Toledo, Cristina Díaz de Heredia   +5 more
doaj   +1 more source

Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia [PDF]

, 2019
The majority of adult patients affected by B-cell acute lymphoblastic leukemia (B-ALL) will relapse after an initial response, while approximately 20% will display primary resistant disease. Patients suffering from relapsed/refractory B-ALL have a very
Lanza, Francesco, Maffini, Enrico, Saraceni, Francesco   +2 more
core   +1 more source

Liquid biopsies and minimal residual disease in myeloid malignancies

Frontiers in Oncology, 2023
Minimal residual disease (MRD) assessment through blood component sampling by liquid biopsies (LBs) is increasingly being investigated in myeloid malignancies.
Sabine Allam, Kristina Nasr, Farhan Khalid, Zunairah Shah, Mahammed Ziauddin Khan Suheb, Sana Mulla, Sindhu Vikash, Maroun Bou Zerdan, Faiz Anwer, Chakra P. Chaulagain   +9 more
doaj   +1 more source

A long-lasting, complete hematologic and cytogenetic remission of chronic myelogenous leukemia after treatment with busulfan alone [PDF]

, 1996
A 44-year-old man suffering from cytogenetically and molecularly proven Philadelphia translocation-positive chronic myelogenous leukemia in chronic phase was treated with busulfan for 18 months and studied during a follow-up period of 13 years ...
Geurts van Kessel, A.H.M. (Ad), Haanen, C. (C.), Hagemeÿer, A. (A.), Mandigers, C., Mensink, E.J.B.M. (Ewald), Plas, D. (D.) van der, Witte, T. de   +6 more
core   +1 more source